Olfactomedin-like 3: Functions in Development and Tumorigenesis

0
0
0

Olfactomedin-like 3: Possible Functions in Embryonic Development and Tumorigenesis

Every day, scientists uncover new genes that hold clues to how our bodies grow, heal, and sometimes fall ill. Olfactomedin-like 3 (OLFML3)—a little-known glycoprotein (a sugar-coated protein) in the Olfactomedin family—is emerging as a critical player in two of medicine’s biggest puzzles: embryonic development (how we form in the womb) and tumorigenesis (how cancers start and spread). While research on OLFML3 is still in its early stages, its unique structure and activity across tissues make it a gene worth watching.

What Is OLFML3?

OLFML3 is a secreted protein made of 406 amino acids. It belongs to the Olfactomedin family—a group of proteins found in all animals that help with early development. What makes OLFML3 special? It has two key structural features:

  • A conserved C-terminal OLF domain: This part is nearly identical across species (humans, mice, pigs), suggesting it’s critical for function (likely helping proteins fold correctly).
  • A variable N-terminal coiled-coil domain: This region is less consistent and probably helps OLFML3 interact with other proteins.

In humans, the OLFML3 gene sits on chromosome 1 (band p13.2) and has three coding regions (exons) separated by two non-coding regions (introns). It’s highly similar to OLFML3 in mice, pigs, and even chickens—proof that its role is evolutionarily important.

Where Is OLFML3 Found?

OLFML3 is differentially expressed—meaning it’s active in some tissues more than others:

  • High levels: Placenta (the organ that supports fetal growth).
  • Moderate levels: Heart, liver.
  • Weak levels: Skeletal muscle, small intestine, lungs, kidneys.
  • Very weak levels: Brain, colon, spleen, thymus.

Two key locations stand out:

  1. Microglia: The brain’s immune cells. OLFML3 is one of the most abundant genes in microglia but is barely detectable in other immune cells (like macrophages).
  2. Tumor stroma: The supportive tissue around cancer cells. OLFML3 is found in vascular endothelial cells (cells lining blood vessels) and pericytes (cells that stabilize vessels)—but not in the cancer cells themselves. This suggests it helps tumors build new blood vessels to grow.

Bioinformatics also links OLFML3 to the female reproductive system (placenta, ovary, endometrium), but researchers haven’t proven a direct link to diseases like endometriosis or ovarian cancer yet.

What Does OLFML3 Do?

OLFML3’s functions split into two major categories: shaping embryonic development and driving tumor growth.

1. Embryonic Development: Building a Healthy Body

OLFML3 plays a quiet but vital role in how we form from a single cell to a complex organism.

  • Microglia maturation: The brain’s immune cells (microglia) need OLFML3 to develop their unique identity. In the first weeks after birth, a signaling molecule called TGFb1 activates OLFML3 via the SMAD2 pathway. This tells microglia to “grow up” and separate from other immune cells (like macrophages). Without OLFML3, microglia can’t mature properly—potentially leading to brain disorders later in life.
  • Prenatal muscle growth: In pigs, OLFML3 helps form primary muscle fibers—the building blocks of adult muscle. A small molecule called miR-155 slows OLFML3 down by breaking down its mRNA (the “message” that makes the protein). Less OLFML3 means fewer primary fibers, which affects muscle size and strength after birth.
  • Dorsal-ventral stability: In frogs (Xenopus) and chickens, OLFML3 keeps the embryo’s back-front (dorsal-ventral) pattern stable. It works with an enzyme called BMP1 to break down Chordin—a protein that shapes the embryo’s axis. Without OLFML3, the embryo’s structure gets disorganized.

2. Tumorigenesis: Helping Cancers Grow and Spread

When it comes to cancer, OLFML3 switches from “builder” to “destroyer.” It helps tumors overcome three key barriers to survival:

  • Angiogenesis: Tumors need new blood vessels to get oxygen and nutrients. OLFML3 boosts this process by binding to BMP4 (a growth factor) and activating the SMAD1/5/8 pathway. This makes blood vessel cells multiply and form new vessels. In lung cancer, blocking a protein called NRP1 (a marker for tumor-initiating cells) lowers OLFML3—slowing growth.
  • Anoikis resistance: Normally, cells die if they lose their attachment to the extracellular matrix (the “scaffold” around tissues)—a process called anoikis. But cancer cells with high OLFML3 avoid this. Studies in lung, nasal, and breast cancer show that anoikis-resistant cells (which spread easily) have 2–3x more OLFML3 than sensitive cells.
  • Epithelial-mesenchymal transition (EMT): Cancer cells become invasive when they lose their “sticky” epithelial properties and turn into mesenchymal cells (which move freely). In breast cancer, two genes—BRMS1 (a metastasis suppressor) and LSD1 (a gene regulator)—turn down OLFML3. Less OLFML3 means fewer invasive cells and slower metastasis.
  • Chemotherapy resistance: Cancer-associated fibroblasts (CAFs)—cells in the tumor stroma—secrete OLFML3. This modifies the extracellular matrix and helps tumors resist drugs like cetuximab (used for head and neck cancer). Patients with high OLFML3 after cetuximab treatment often have worse outcomes.

OLFML3 and Human Disease

OLFML3’s link to health and disease goes beyond development and cancer:

  • Cancer biomarkers: High OLFML3 levels correlate with worse survival in microglioma, breast, lung, and colon cancer. It could one day be used to screen for early-stage tumors or predict treatment response.
  • Obesity: Fat pigs have less OLFML3 in their backfat than lean pigs. This suggests OLFML3 might regulate fat storage—making it a potential marker for obesity risk.
  • Glaucoma: Mutations in OLFML3 are linked to open-angle glaucoma (a leading cause of blindness). Abnormal OLFML3 in eye microglia may disrupt the eye’s drainage system, raising pressure and damaging the optic nerve.
  • ALS (Lou Gehrig’s disease): OLFML3 is missing in the spinal cord microglia of ALS patients. A molecule called miR-155 (which is overactive in ALS) turns down OLFML3, weakening microglia and accelerating disease progression. Blocking miR-155 restores OLFML3 and extends survival in mouse models.
  • Tissue engineering: Scientists are adding OLFML3 to electrospun polymer scaffolds—materials that mimic the extracellular matrix—to speed up wound healing. OLFML3 helps new blood vessels form, which is key for repairing skin, bones, or organs.

The Future of OLFML3 Research

OLFML3 is a gene of contradictions: it builds healthy embryos but fuels deadly cancers; it supports immune cells but fails them in ALS. What we know so far is just the tip of the iceberg. Future studies could:

  • Uncover how OLFML3 interacts with other proteins in the tumor microenvironment.
  • Test OLFML3-targeted therapies (like antibodies or siRNAs) for cancer or glaucoma.
  • Explore its role in female reproductive health (e.g., preeclampsia or infertility).

One thing is clear: OLFML3 is more than just a “new gene”—it’s a window into how our bodies balance growth and disease. As we learn more, it could become a powerful tool for diagnosing and treating some of medicine’s most challenging conditions.

  1. Anholt RR. Olfactomedin proteins: central players in development and disease. Front Cell Dev Biol 2014;26:1–10. doi: doi.org/10.3389/fcell.2014.00006
  2. Zeng LC, Han ZG, Ma WJ. Elucidation of subfamily segregation and intramolecular coevolution of the olfactomedin-like proteins by comprehensive polygenetic analysis and gene expression pattern assessment. FEBS Lett 2005;579:5443–5453. doi: doi.org/10.1016/j.febslet.2005.08.064
  3. Barembaum M, Moreno TA, Labonne C, Sechrist J, Bronner-Fraser M. Noelin-1 is a secreted glycoprotein involved in generation of the neural crest. Nat Cell Biol 2000;2:219–225. doi: doi.org/10.1038/35008643
  4. Tomarev SI, Nakaya N. Olfactomedin domain-containing proteins: possible mechanisms of action and functions in normal development and pathology. Mol Neurobiol 2009;40:122–138. doi: doi.org/10.1007/s12305-009-8076-x
  5. Murakami K, Kikugawa S, Kobayashi Y, Uehara S, Suzuki T, Kato H, et al. Olfactomedin-like protein OLFML1 inhibits Hippo signaling and mineralization in osteoblasts. Biochem Biophys Res Commun 2018;505:419–425. doi: doi.org/10.1016/j.bbrc.2018.09.112
  6. Wan B, Zhou YB, Zhang X, Zhu H, Huo K, Han ZG. hOLFML1, a novel secreted glycoprotein, enhances the proliferation of human cancer cell lines in vitro. FEBS Lett 2008;582:3185–3192. doi: doi.org/10.1016/j.febslet.2008.08.009
  7. Rodriguez-Sanchez IP, Garza-Rodriguex ML, Mohamed-Noriega K, Voruganti VS, Tejero ME, Delgado-Enciso I, et al. Olfactomedin-like 3(OLFML3) gene expression in baboon and human ocular tissue: cornea, lens, uvea, and retina. J Med Primatol 2013;42:105–111. doi: doi.org/10.1111/jmp.12037
  8. Zeng LC, Liu F, Zhang X, Zhu ZD, Wang ZQ, Han ZG, et al. hOLF44, a secreted glycoprotein with distinct expression pattern, belongs to an uncharacterized olfactomedin-like subfamily newly identified by phylogenetic analysis. FEBS Lett 2004;571:74–80. doi: doi.org/10.1016/j.febslet.2004.06.059
  9. Zhao S, Zhang J, Hou X, Zan L, Wang N, Tang Z, et al. OLFML3 expression is decreased during prenatal muscle development and regulated by microRNA-155 in pigs. Int J Biol Sci 2012;8:459–469. doi: doi.org/10.7150/ijbs.3821
  10. Miljkovic-Licina M, Hammel P, Garrido-Urbani S, Lee BP, Meguenani M, Chaabane C, et al. Targeting olfactomedin-like 3 inhibits tumour growth by impairing angiogenesis and pericyte coverage. Mol Cancer Ther 2012;11:2588–2599. doi: doi.org/10.1158/1535-7163
  11. Neidert N, von Ehr A, Zoller T, Spittau B. Microglia-specific expression of OLFML3 is directly regulated by transforming growth factor b 1-induced SMAD2 signaling. Front Immunol 2018;9:1728. doi: doi.org/10.3389/fimmu.2018.01728
  12. Caballero M, Borras T. Inefficient processing of an olfactomedin-deficient myocilin mutant: potential physiological relevance to glaucoma. Biochem Biophys Res Commun 2001;282:662–670. doi: doi.org/10.1006/bbrc.2001.4624
  13. Chiu IM, Morimoto ETA, Goodarzi H, Liao JT, O’Keeffe S, Phatnani HP, et al. A neurodegeneration-specific gene-expression signature of acutely isolated microglia from an amyotrophic lateral sclerosis mouse model. Cell Rep 2013;4:385–401. doi: doi.org/10.1016/j.celrep.2013.06.018
  14. Sakuragi M, Sasai N, Ikeya M, Kawada M, Onai T, Katahira T, et al. Functional analysis of chick ONT1 reveals distinguishable activities among olfactomedin-related signaling factors. Mech Dev 2006;123:114–123. doi: doi.org/10.1016/j.mod.2005.11.005
  15. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumour microenvironment. Cancer Cell 2012;21:309–322. doi: doi.org/10.1016/j.ccr.2012.02.022
  16. De Wever O, Demetter P, Mareel M, Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008;123:2229–2238. doi: doi.org/10.1002/ijc.23925
  17. Bennett ML, Bennett FC, Liddelow SA, Ajami B, Zamanian JL, Fernhoff NB, et al. New tools for studying microglia in the mouse and human CNS. Proc Natl Acad Sci U S A 2016;113:E1738–E1746. doi: doi.org/10.1073/pnas.1525528113
  18. Attaai A, Neidert N, Von Ehr A, Potru PS, Zöller T, Spittau B. Postnatal maturation of microglia is associated with alternative activation and activated TGF-b signaling. Glia 2018;66:1695–1708. doi: doi.org/10.1002/glia.23332
  19. Yang L, Li C, Liang F, Fan Y, Zhang S. MiRNA-155 promotes proliferation by targeting caudal-type homeobox 1 (CDX1) in glioma cells. Biomed Pharmacother 2017;95:1759–1764. doi: doi.org/10.1016/j.biopha.2017.08.088
  20. Seok HY, Tatsuguchi M, Callis TE, Ha A, Pu WT, Wang DZ. miRNA-155 inhibits expression of the MEF2A protein to repress skeletal muscle differentiation. J Biol Chem 2011;286:35339–35346. doi: doi.org/10.1074/jbc.M111.273276
  21. Inomata H, Haraguchi T, Sasai Y. Robust stability of the embryonic axial pattern requires a secreted scaffold for Chordin degradation. Cell 2008;134:854–865. doi: doi.org/10.1016/j.cell.2008.07.008
  22. Paper W, Kroeber M, Heersink S, Stephan DA, Fuchshofer R, Russell P, et al. Elevated amounts of myocilin in the aqueous humor of transgenic mice cause significant changes in ocular gene expression. Exp Eye Res 2008;87:257–267. doi: doi.org/10.1016/j.exer.2008.06.006
  23. Mukhopadhyay A, Talukdar S, Bhattacharjee A, Ray K. Bioinformatic approaches for identification and characterization of olfactomedin related genes with a potential role in pathogenesis of ocular disorders. Mol Vis 2004;10:304–314.
  24. Ge G, Fernandea CA, Moses MA, Greenspan DS. Bone morphogenetic protein 1 processes prolactin to a 17-kDa antiangiogenic factor. Proc Natl Acad Sci U S A 2007;104:10010–10015. doi: doi.org/10.1073/pnas.0704179104
  25. Davic L, Mallet C, Keramidas M, Lamande N, Gasc JM, Dupuis-Girod S, et al. Bone morphogenetic protein-

Was this helpful?

0 / 0